{"id":"meropenem-intravenous","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-8","effect":"Nausea"},{"rate":"2-5","effect":"Vomiting"},{"rate":"2-4","effect":"Rash"},{"rate":"2-3","effect":"Phlebitis at injection site"},{"rate":"0.5-1","effect":"Seizures (in meningitis or renal impairment)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Meropenem is a carbapenem antibiotic that penetrates bacterial cell walls and binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and causing cell wall disruption and bacterial death. It has activity against a wide range of gram-positive and gram-negative bacteria, including anaerobes, making it useful for serious infections caused by susceptible organisms.","oneSentence":"Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:51.147Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections (meningitis, intra-abdominal infections, pneumonia, sepsis)"},{"name":"Hospital-acquired and community-acquired infections caused by susceptible organisms"}]},"trialDetails":[{"nctId":"NCT06080698","phase":"NA","title":"Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-02-22","conditions":"Gram-negative Bacteremia","enrollment":1030},{"nctId":"NCT07445282","phase":"PHASE4","title":"This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever","status":"COMPLETED","sponsor":"Sheikh Zayed Medical College","startDate":"2025-05-14","conditions":"Extensively Drug-Resistant Typhoid Fever, Typhoid Fever, Salmonella Typhi Infection","enrollment":90},{"nctId":"NCT04478721","phase":"PHASE3","title":"Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-12-15","conditions":"Bacteremia","enrollment":334},{"nctId":"NCT07314281","phase":"PHASE4","title":"Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever","status":"RECRUITING","sponsor":"Indus Hospital and Health Network","startDate":"2025-04-22","conditions":"Enteric Fever","enrollment":40},{"nctId":"NCT07084428","phase":"","title":"Pancreatic Antibiotic Concentration Evaluation Assessment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brno University Hospital","startDate":"2024-01-15","conditions":"Acute Pancreatic Fluid Collection, Acute Pancreatitis","enrollment":40},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":"Febrile Urinary Tract Infection","enrollment":560},{"nctId":"NCT03543436","phase":"PHASE3","title":"Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-01-04","conditions":"Urinary Tract Infections","enrollment":29},{"nctId":"NCT06916156","phase":"PHASE1","title":"Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants","status":"COMPLETED","sponsor":"Antabio","startDate":"2025-04-28","conditions":"Pharmacokinetics Study on Healthy Volunteers Adults","enrollment":26},{"nctId":"NCT07124468","phase":"PHASE1","title":"Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09-13","conditions":"Infections","enrollment":16},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT07122596","phase":"PHASE4","title":"EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS","status":"COMPLETED","sponsor":"Pakistan Navy Station Shifa Hospital","startDate":"2024-04-01","conditions":"Sepsis, Bacterial Infection","enrollment":150},{"nctId":"NCT07113587","phase":"PHASE2, PHASE3","title":"Pharmacokinetics of Intraperitoneal and Intravenous Meropenem, Ampicillin, Aztreonam and Ciprofloxacin in Automated Peritoneal Dialysis Patients Without Peritonitis","status":"COMPLETED","sponsor":"Karl Landsteiner Insitute for Nephrology and Haemato-Oncology","startDate":"2014-04-08","conditions":"Peritoneal Dialysis-associated Peritonitis, Peritoneal Dialysis (PD), Pharmacokinetics","enrollment":24},{"nctId":"NCT05922124","phase":"PHASE4","title":"Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2024-09-01","conditions":"Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia","enrollment":734},{"nctId":"NCT06527677","phase":"PHASE1","title":"Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects","status":"COMPLETED","sponsor":"Antabio","startDate":"2024-07-19","conditions":"Renal Impairment","enrollment":41},{"nctId":"NCT06184659","phase":"PHASE4","title":"Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis","status":"RECRUITING","sponsor":"Scandinavian Critical Care Trials Group","startDate":"2025-06-26","conditions":"Sepsis, Septic Shock","enrollment":5800},{"nctId":"NCT06051513","phase":"NA","title":"Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","status":"RECRUITING","sponsor":"Southeast University, China","startDate":"2023-11-27","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":404},{"nctId":"NCT05905913","phase":"PHASE1","title":"FiH Study to Assess Safety and PK of SAD and MAD of ANT3310 Alone and in Combination With Meropenem in Healthy Subjects","status":"COMPLETED","sponsor":"Antabio","startDate":"2023-04-12","conditions":"Healthy Volunteers","enrollment":72},{"nctId":"NCT05105035","phase":"PHASE2","title":"Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients","status":"COMPLETED","sponsor":"Arrevus Inc.","startDate":"2022-06-14","conditions":"Melioidosis","enrollment":125},{"nctId":"NCT06198764","phase":"PHASE3","title":"A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-07-06","conditions":"Mental Health Issue","enrollment":80},{"nctId":"NCT05293132","phase":"PHASE2, PHASE3","title":"Effect of Montelukast Versus Co Enzyme in Sepsis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-02-01","conditions":"Sepsis","enrollment":90},{"nctId":"NCT03174184","phase":"PHASE2","title":"Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-08-23","conditions":"Tuberculosis, Pulmonary","enrollment":112},{"nctId":"NCT03630081","phase":"PHASE3","title":"Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)","status":"UNKNOWN","sponsor":"Wockhardt","startDate":"2024-01","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":1004},{"nctId":"NCT05896930","phase":"PHASE2","title":"Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"TASK Applied Science","startDate":"2017-11-09","conditions":"Pulmonary Tuberculosis","enrollment":134},{"nctId":"NCT05565222","phase":"PHASE3","title":"Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-03-11","conditions":"Sepsis, Septic Shock","enrollment":600},{"nctId":"NCT05204368","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40)","status":"UNKNOWN","sponsor":"Evopoint Biosciences Inc.","startDate":"2023-03-30","conditions":"Complicated Urinary Tract Infection Including Acute Pyelonephritis","enrollment":780},{"nctId":"NCT03830333","phase":"PHASE3","title":"Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-20","conditions":"Complicated Intra-abdominal Infections","enrollment":268},{"nctId":"NCT05393505","phase":"PHASE4","title":"Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2022-10-24","conditions":"Neutropenic Fever","enrollment":344},{"nctId":"NCT05226923","phase":"PHASE1","title":"Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects","status":"COMPLETED","sponsor":"Sumitovant Biopharma, Inc.","startDate":"2022-01-12","conditions":"Bacterial Infections","enrollment":123},{"nctId":"NCT05340530","phase":"PHASE1","title":"To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-04","conditions":"Infections","enrollment":56},{"nctId":"NCT05058105","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD)","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-10-08","conditions":"Healthy","enrollment":40},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04030741","phase":"PHASE2, PHASE3","title":"Non-operative Treatment of Acute Non-perforated Appendicitis","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2018-09-01","conditions":"Acute Appendicitis","enrollment":180},{"nctId":"NCT04671589","phase":"PHASE4","title":"Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic.","status":"UNKNOWN","sponsor":"Mabaret Al-Asafara Hospitals","startDate":"2021-06","conditions":"Drug Toxicity","enrollment":48},{"nctId":"NCT04489459","phase":"PHASE4","title":"Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae","status":"UNKNOWN","sponsor":"Al-Azhar University","startDate":"2019-09-21","conditions":"Treatment of Blood Stream Infections Due to Multidrug-Resistant Klebsiella Pneumoniae","enrollment":60},{"nctId":"NCT02070757","phase":"PHASE3","title":"Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-09-02","conditions":"Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases","enrollment":726},{"nctId":"NCT02047773","phase":"PHASE4","title":"Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2014-01","conditions":"Bronchiectasis","enrollment":90},{"nctId":"NCT03645668","phase":"PHASE4","title":"Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients","status":"COMPLETED","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-01-30","conditions":"Sepsis","enrollment":80},{"nctId":"NCT02894684","phase":"PHASE4","title":"Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis","status":"COMPLETED","sponsor":"Liverpool Heart and Chest Hospital NHS Foundation Trust","startDate":"2017-01","conditions":"Cystic Fibrosis, Infection, Pseudomonas","enrollment":16},{"nctId":"NCT03477422","phase":"PHASE3","title":"CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria","status":"COMPLETED","sponsor":"Venus Remedies Limited","startDate":"2014-01-11","conditions":"Urinary Tract Infection Complicated, Acute Pyelonephritis","enrollment":230},{"nctId":"NCT02142751","phase":"PHASE3","title":"Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2014-07","conditions":"Infection Due to ESBL Escherichia Coli","enrollment":161},{"nctId":"NCT03344627","phase":"NA","title":"Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-11-27","conditions":"Sepsis, Septic Shock, Critical Illness","enrollment":76},{"nctId":"NCT01445678","phase":"PHASE3","title":"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-12-23","conditions":"Complicated Intra-abdominal Infection","enrollment":494},{"nctId":"NCT01147640","phase":"PHASE2","title":"Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-06-25","conditions":"Complicated Intra-abdominal Infection","enrollment":122},{"nctId":"NCT03136796","phase":"","title":"Glycocalyx Damage and Beta-lactam Antibiotics in Surgical Critically Ill","status":"COMPLETED","sponsor":"University Hospital Hradec Kralove","startDate":"2017-05-02","conditions":"Critical Illness","enrollment":20},{"nctId":"NCT01970371","phase":"PHASE3","title":"A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)","status":"COMPLETED","sponsor":"Achaogen, Inc.","startDate":"2014-09-16","conditions":"Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE","enrollment":69},{"nctId":"NCT02486627","phase":"PHASE3","title":"A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)","status":"COMPLETED","sponsor":"Achaogen, Inc.","startDate":"2016-01-11","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":609},{"nctId":"NCT02168816","phase":"PHASE2","title":"Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis","status":"TERMINATED","sponsor":"Loyola University","startDate":"2014-03-19","conditions":"Osteomyelitis","enrollment":30},{"nctId":"NCT03174795","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-11","conditions":"Urinary Tract Infections","enrollment":20},{"nctId":"NCT03182504","phase":"PHASE1","title":"A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-06-15","conditions":"Gram-negative Bacterial Infections","enrollment":21},{"nctId":"NCT00619710","phase":"PHASE3","title":"Complicated Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-02","conditions":"Skin Infection, Abscess, Cellulitis","enrollment":1000},{"nctId":"NCT02732327","phase":"PHASE2","title":"Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2016-05-17","conditions":"Neoplasms, Febrile Neutropenia","enrollment":2},{"nctId":"NCT02972255","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-10-31","conditions":"Healthy Volunteers","enrollment":46},{"nctId":"NCT02344563","phase":"PHASE4","title":"Bioequivalence of Two Formulations of Meropenem Intravenous Injection","status":"COMPLETED","sponsor":"Yung Shin Pharm. Ind. Co., Ltd.","startDate":"2014-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT01455246","phase":"PHASE2, PHASE3","title":"Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis","status":"TERMINATED","sponsor":"University of Padova","startDate":"2010-10","conditions":"Cirrhosis, Ascites, Nosocomial Spontaneous Bacterial Peritonitis","enrollment":32},{"nctId":"NCT02212392","phase":"PHASE1, PHASE2","title":"Comparing the Outcome in Patients of Acute Pancreatitis, With and Without Prophylactic Antibiotics","status":"COMPLETED","sponsor":"Benazir Bhutto Hospital, Rawalpindi","startDate":"2013-01","conditions":"Acute Pancreatitis","enrollment":90},{"nctId":"NCT01110382","phase":"PHASE3","title":"A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-12","conditions":"Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute","enrollment":41},{"nctId":"NCT00307099","phase":"PHASE3","title":"Comparative Antibiotic Therapy for Subjects With Pulmonary Infiltrates in the ICU","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-10","conditions":"Bacterial Infection","enrollment":460},{"nctId":"NCT01572558","phase":"NA","title":"Conservative Treatment of Acute Appendicitis in Children","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2012-02","conditions":"Appendicitis, Child","enrollment":51},{"nctId":"NCT00534287","phase":"PHASE3","title":"Comparison of Two Antibiotic Regimen (Meropenem Versus Meropenem+Moxifloxacin)in the Treatment of Severe Sepsis and Septic Shock","status":"COMPLETED","sponsor":"Kompetenznetz Sepsis","startDate":"2007-10","conditions":"Severe Sepsis, Septic Shock","enrollment":600},{"nctId":"NCT01044719","phase":"PHASE4","title":"Duration of Antibiotics in Infective Exacerbations of Cystic Fibrosis","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2010-01","conditions":"Cystic Fibrosis","enrollment":240}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"BLOOD BILIRUBIN INCREASED"},{"count":1,"reaction":"BLOOD CALCIUM DECREASED"},{"count":1,"reaction":"BLOOD CULTURE POSITIVE"},{"count":1,"reaction":"BLOOD SODIUM DECREASED"},{"count":1,"reaction":"COLITIS"},{"count":1,"reaction":"ENDOCARDITIS"},{"count":1,"reaction":"ENTEROCOCCAL BACTERAEMIA"},{"count":1,"reaction":"FLUID OVERLOAD"}],"_approvalHistory":[],"publicationCount":855,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Generic name: Meropenem","Pharmaceutical form: solution for infusion","ATC code: J01D5"],"phase":"phase_3","status":"active","brandName":"Meropenem intravenous","genericName":"Meropenem intravenous","companyName":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","companyId":"fundaci-n-p-blica-andaluza-para-la-gesti-n-de-la-investigaci-n-en-sevilla","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections (meningitis, intra-abdominal infections, pneumonia, sepsis), Hospital-acquired and community-acquired infections caused by susceptible organisms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}